- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Sapphire.
Displaying page 1 of 1.
EudraCT Number: 2006-001196-38 | Sponsor Protocol Number: D1448C00014 | Start Date*: 2006-06-14 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) as Mono-Therapy in t... | ||
Medical condition: Major Depressive Disorder (MDD) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004648-12 | Sponsor Protocol Number: CLS1003-301 | Start Date*: 2018-01-15 |
Sponsor Name:Clearside Biomedical, Inc. | ||
Full Title: SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION | ||
Medical condition: Retinal Vein Occlusion | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) HU (Completed) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) PT (Completed) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-002156-84 | Sponsor Protocol Number: 63623872FLZ3001 | Start Date*: 2018-05-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, a... | |||||||||||||
Medical condition: Influenza A Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001043-41 | Sponsor Protocol Number: 516-005 | Start Date*: 2020-11-03 | |||||||||||
Sponsor Name:Mirati Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Plat... | |||||||||||||
Medical condition: Non-Squamous Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) HU (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004079-11 | Sponsor Protocol Number: D5495C00002 | Start Date*: 2019-06-28 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricaemia | ||
Medical condition: Chronic kidney disease and hyperuricaemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) SK (Completed) CZ (Completed) ES (Ongoing) IT (Completed) RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002019-25 | Sponsor Protocol Number: M11-646 | Start Date*: 2013-03-13 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatme... | |||||||||||||
Medical condition: Chronic Hepatitis C Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) HU (Completed) DE (Completed) AT (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001771-14 | Sponsor Protocol Number: SRK-015-004 | Start Date*: 2023-05-08 | |||||||||||
Sponsor Name:Scholar Rock, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigat... | |||||||||||||
Medical condition: Spinal Muscular Atrophy (SMA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002035-29 | Sponsor Protocol Number: M13-098 | Start Date*: 2013-01-24 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co administered with Ribavirin (RBV) in Treat... | |||||||||||||
Medical condition: Chronic Hepatitis C Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) CZ (Completed) PT (Completed) IE (Completed) NL (Completed) IT (Completed) DK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005314-34 | Sponsor Protocol Number: SRK-015-003 | Start Date*: 2022-06-01 | |||||||||||
Sponsor Name:Scholar Rock, Inc. | |||||||||||||
Full Title: Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or ... | |||||||||||||
Medical condition: Spinal Muscular Atrophy (SMA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) ES (Ongoing) NL (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005802-38 | Sponsor Protocol Number: AP12009-G005 | Start Date*: 2009-03-19 | ||||||||||||||||
Sponsor Name:Antisense Pharma GmbH | ||||||||||||||||||
Full Title: Efficacy and Safety of AP 12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or Secondary Glioblastoma (WHO grade IV) as Compared to Standard Chemotherapy: ... | ||||||||||||||||||
Medical condition: Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or secondary Glioblastoma (WHO grade IV) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) FR (Completed) ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
